Enhancing neuro-oncology care through equity-driven applications of artificial intelligence
The disease course and clinical outcome for brain tumor patients depend not only on the
molecular and histological features of the tumor but also on the patient's demographics and …
molecular and histological features of the tumor but also on the patient's demographics and …
Economic income and survival in patients affected by glioblastoma: A systematic review and meta-analysis
V Di Nunno, L Gatto, M Aprile, S Bartolini… - Neuro-Oncology …, 2024 - academic.oup.com
Background Within socio-economic variables, economic income has been associated with
the prognosis of patients with glioblastoma. However, studies investigating this issue …
the prognosis of patients with glioblastoma. However, studies investigating this issue …
Racial/ethnic disparities in all-cause and cause-specific death among children with malignant central nervous system tumours: a registry-based cohort retrospective …
H Wang, B Yao, T Tang, M Gong, Y Ma, X Wu… - …, 2024 - thelancet.com
Background It is generally recognized that there is unequal mortality in childhood central
nervous system (CNS) malignancy in the United States (US), but little is known about the …
nervous system (CNS) malignancy in the United States (US), but little is known about the …
Neuro-oncologic Emergencies
OBJECTIVE Neuro-oncologic emergencies have become more frequent as cancer remains
one of the leading causes of death in the United States, second only to heart disease. This …
one of the leading causes of death in the United States, second only to heart disease. This …
Financial challenges of being on long-term, high-cost medications
C Elshiekh, R Rudà, ERS Cliff, F Gany… - Neuro-Oncology …, 2025 - academic.oup.com
The isocitrate dehydrogenase (IDH) inhibitor, vorasidenib, may offer a promising new
treatment option for patients with IDH-mutant gliomas. However, the indefinite nature of this …
treatment option for patients with IDH-mutant gliomas. However, the indefinite nature of this …
Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort
JA Budhu, UN Chukwueke, S Jackson, EQ Lee… - Neuro …, 2024 - academic.oup.com
Despite major strides in cancer research and therapy, these advances have not been
equitable across race and ethnicity. Historically marginalized groups (HMG) are more likely …
equitable across race and ethnicity. Historically marginalized groups (HMG) are more likely …
[PDF][PDF] Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO
JA Budhu, UN Chukwueke, S Jackson, EQ Lee… - 2023 - scholar.archive.org
Despite major strides in cancer research and therapy, these advances have not been
equitable across race and ethnicity. Historically marginalized groups (HMG) are more likely …
equitable across race and ethnicity. Historically marginalized groups (HMG) are more likely …